全文获取类型
收费全文 | 39379篇 |
免费 | 2187篇 |
国内免费 | 200篇 |
专业分类
耳鼻咽喉 | 379篇 |
儿科学 | 580篇 |
妇产科学 | 400篇 |
基础医学 | 5199篇 |
口腔科学 | 1168篇 |
临床医学 | 2542篇 |
内科学 | 9828篇 |
皮肤病学 | 953篇 |
神经病学 | 2666篇 |
特种医学 | 1555篇 |
外科学 | 6872篇 |
综合类 | 168篇 |
一般理论 | 2篇 |
预防医学 | 1082篇 |
眼科学 | 741篇 |
药学 | 2887篇 |
中国医学 | 56篇 |
肿瘤学 | 4688篇 |
出版年
2023年 | 194篇 |
2021年 | 809篇 |
2020年 | 449篇 |
2019年 | 581篇 |
2018年 | 721篇 |
2017年 | 644篇 |
2016年 | 726篇 |
2015年 | 756篇 |
2014年 | 974篇 |
2013年 | 1221篇 |
2012年 | 1930篇 |
2011年 | 2122篇 |
2010年 | 1245篇 |
2009年 | 1093篇 |
2008年 | 1824篇 |
2007年 | 1857篇 |
2006年 | 1882篇 |
2005年 | 1936篇 |
2004年 | 1807篇 |
2003年 | 1811篇 |
2002年 | 1724篇 |
2001年 | 1353篇 |
2000年 | 1388篇 |
1999年 | 1257篇 |
1998年 | 486篇 |
1997年 | 403篇 |
1996年 | 336篇 |
1995年 | 332篇 |
1994年 | 287篇 |
1993年 | 276篇 |
1992年 | 849篇 |
1991年 | 762篇 |
1990年 | 756篇 |
1989年 | 721篇 |
1988年 | 733篇 |
1987年 | 631篇 |
1986年 | 632篇 |
1985年 | 613篇 |
1984年 | 407篇 |
1983年 | 333篇 |
1982年 | 162篇 |
1980年 | 140篇 |
1979年 | 330篇 |
1978年 | 209篇 |
1977年 | 164篇 |
1975年 | 153篇 |
1974年 | 213篇 |
1973年 | 151篇 |
1972年 | 167篇 |
1971年 | 150篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
1.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
2.
3.
4.
5.
6.
Atsushi Hata Takahiro Nakajima Keisuke Matsusaka Masaki Fukuyo Junichi Morimoto Takayoshi Yamamoto Yuichi Sakairi Bahityar Rahmutulla Satoshi Ota Hironobu Wada Hidemi Suzuki Hisahiro Matsubara Ichiro Yoshino Atsushi Kaneda 《International journal of cancer. Journal international du cancer》2020,146(2):388-399
7.
8.
9.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217
10.
Kosuke Yoshihara Takayuki Enomoto Daisuke Aoki Yoh Watanabe Junzo Kigawa Nobuhiro Takeshima Hyoe Inomata Kana Hattori Masahisa Jinushi Hitoshi Tsuda Toru Sugiyama 《Cancer science》2020,111(9):3350-3358
Whether germline (g) breast cancer susceptibility gene (BRCA) mutations are located within or outside the ovarian cancer cluster region (OCCR) (1380‐4062 bp for gBRCA1, and between 3249‐5681 bp and 6645‐7471 bp for gBRCA2) may influence risk variations for ovarian cancers. This ad hoc analysis of the CHARLOTTE epidemiological study in Japan assessed the distribution of gBRCA1/2 mutations in patients with newly diagnosed ovarian cancer, and investigated an association between gBRCA1/2 mutation locations and ovarian cancer risk. Differences in patient background and clinical characteristics in subgroups stratified by gBRCA1/2 mutation locations were also evaluated. We analyzed the data of 93 patients (14.7%) from the CHARLOTTE study who were positive for gBRCA1/2 mutations. After excluding 16 cases with L63X founder mutation, 28 (65.1%) of gBRCA1 mutations were within the OCCR. Of 30 gBRCA2 mutations, 15 (50.0%) were within the OCCR. Of 27 patients (one patient excluded for unknown family history) with gBRCA1 mutations located in the OCCR, 11 (40.7%) had a family history of ovarian cancer; the proportion of patients with a family history of ovarian cancer and gBRCA1 mutations outside the OCCR was lower (13.3%). Sixty percent of patients with gBRCA1 mutations outside the OCCR had a family history of breast cancer; the proportion of patients with a family history of breast cancer and gBRCA1 mutations within the OCCR was relatively lower (33.3%). Understanding the mutation locations may contribute to more accurate risk assessments of susceptible individuals and early detection of ovarian cancer among gBRCA mutation carriers. 相似文献